What are Celltrion’s future schedule after the entry to the U.S. market?
The future direction of ‘Remsima,’ a Celltrion’s biosimilar antibody, has attracted attention as receiving the approval recommendation from the U.S. FDA Arthritis Advisory Committee.
Celltrion, expecting the final approval of Remsima this April, is now waiting for the confirmation of generic sub...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
